Literature DB >> 25934338

New approaches for cancer immunotherapy.

Ayfer Karlitepe1, Ozgun Ozalp, Cigir Biray Avci.   

Abstract

Immunotherapy is a promising field that offers alternative methods for treatment of cancer. The current strategy consists of cancer vaccines, monoclonal antibodies, and cellular therapies. Cancer vaccines aim to eradicate cancer cells via immune system. Thus, they may attack these cells derived from any type of cancer, besides their role in preventing cancer. Lymphocytes and dendritic cells are often used in cellular therapy. In addition, monoclonal antibodies are designed to target specific antigens found in cancer cells. Currently, at least 12 clinically approved monoclonal antibodies are being used and many cancer vaccines are being developed with ongoing phase studies for cancer therapy. Relevant studies are focused on glioma and several other cancer types. Correspondingly, the combination of effective methods may enhance the efficacy of immunotherapy. It is thought that particularly immune checkpoint inhibitors will play a crucial role in immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25934338     DOI: 10.1007/s13277-015-3491-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

Review 1.  Antibody therapy of cancer.

Authors:  Andrew M Scott; Jedd D Wolchok; Lloyd J Old
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 2.  Future approaches in immunotherapy.

Authors:  Brian Rini
Journal:  Semin Oncol       Date:  2014-09-07       Impact factor: 4.929

Review 3.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

4.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

Review 5.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

6.  Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning.

Authors:  Akira Iizuka; Masaru Komiyama; Chie Oshita; Akiko Kume; Tadashi Ashizawa; Koichi Mitsuya; Nakamasa Hayashi; Yoko Nakasu; Ken Yamaguchi; Yasuto Akiyama
Journal:  Immunol Lett       Date:  2014-02-15       Impact factor: 3.685

Review 7.  Adoptive T cell therapy for cancer in the clinic.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

Review 8.  HDAC inhibitors and immunotherapy; a double edged sword?

Authors:  Michiel Kroesen; Paul Gielen; Ingrid C Brok; Inna Armandari; Peter M Hoogerbrugge; Gosse J Adema
Journal:  Oncotarget       Date:  2014-08-30

9.  Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.

Authors:  B Thaci; A U Ahmed; I V Ulasov; D A Wainwright; P Nigam; B Auffinger; A L Tobias; Y Han; L Zhang; K-S Moon; M S Lesniak
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

10.  Immunovirotherapy for glioblastoma.

Authors:  Jianfang Ning; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  Cell Cycle       Date:  2013-11-14       Impact factor: 4.534

View more
  12 in total

1.  A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma.

Authors:  Rajeev K Tyagi; Rajesh Parmar; Naisargee Patel
Journal:  Hum Vaccin Immunother       Date:  2016-11-30       Impact factor: 3.452

Review 2.  Monoclonal antibodies in cancer immunotherapy.

Authors:  Ilgin Kimiz-Gebologlu; Sultan Gulce-Iz; Cigir Biray-Avci
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

3.  Cancer Immunotherapy, Part 3: Challenges and Future Trends.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-08

4.  Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer.

Authors:  Jianhua Zhong; Yan Chen; Xinhui Liao; Jiaqiang Li; Han Wang; Chenglong Wu; Xiaowen Zou; Gang Yang; Jing Shi; Liya Luo; Litao Liu; Jianping Deng; Aifa Tang
Journal:  Tumour Biol       Date:  2015-12-22

5.  Cancer Immunotherapy, Part 1: Current Strategies and Agents.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-06

Review 6.  Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.

Authors:  Francesco S Mennini; Chiara Bini; Andrea Marcellusi; Michele Del Vecchio
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

Review 7.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Authors:  Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

8.  Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-07

Review 9.  Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies.

Authors:  Federica Liotti; Nella Prevete; Giancarlo Vecchio; Rosa Marina Melillo
Journal:  F1000Res       Date:  2019-02-28

Review 10.  Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.

Authors:  Andrew M K Law; Fatima Valdes-Mora; David Gallego-Ortega
Journal:  Cells       Date:  2020-02-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.